Last reviewed · How we verify
Merkel cell carcinoma
Approved treatments
- PF-07220060 + PF-07104091 combination dose escalation · Pfizer
- Bavencio · Merck KGaA
Bavencio blocks the PD-L1 protein, allowing the immune system to recognize and attack cancer cells. - Bavencio · Pfizer
- ZYNYZ · INCYTE CORP
- Zynyz · Incyte Corp
Zynyz works by blocking the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells.
Clinical guidelines
- FDA label — 1L
BAVENCIO (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Merkel cell carcinoma patent landscape — cliff calendar, originator estates, attackable patents
- Merkel cell carcinoma treatment landscape brief
- Merkel cell carcinoma treatment updates RSS
Frequently asked questions about Merkel cell carcinoma
What drugs treat Merkel cell carcinoma?
Tracked treatments include PF-07220060 + PF-07104091 combination dose escalation, Bavencio, ZYNYZ, Zynyz.
What is the treatment for Merkel cell carcinoma?
Standard treatment for Merkel cell carcinoma includes PF-07220060 + PF-07104091 combination dose escalation, Bavencio, ZYNYZ, Zynyz. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Merkel cell carcinoma?
FDA label publishes guidelines for Merkel cell carcinoma. 1 guideline references tracked.
Related
- Treatment landscape: Merkel cell carcinoma patent cliff · Merkel cell carcinoma CI report
- Treatment: PF-07220060 + PF-07104091 combination dose escalation · Pfizer
- Treatment: Bavencio · Merck KGaA
- Treatment: Bavencio · Pfizer
- Treatment: ZYNYZ · INCYTE CORP
- Treatment: Zynyz · Incyte Corp
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing